By Renaud Balsse, Biotech Integrated Solutions Manager, at Pall
The market for gene therapies is becoming more competitive as companies recognize the opportunities to deliver new therapeutics to patients. Amidst this competition, developers need access to more efficient manufacturing operations that can cut time and costs. Conventional biopharma processes rely on multiple unit operations and are often not suited to producing the doses required for a gene therapy; some therapies require very few doses and, therefore, small batch sizes; others may require many or much larger doses and therefore larger batch sizes. Flexibility is important – but there is also room for improvement in terms of establishing consistent, scalable production processes.
Gene therapies can have a significant impact on patients – in many cases, treating previously intractable conditions. Developers are keen to accelerate time to market, but engineering expertise is required to overcome manufacturing sticking points. Pall offers integrated solutions that bring together various processes into a single, coordinated, and controlled environment. This approach should enable the medicines of the future to reach patients faster by trimming the excess off manufacturing protocols.